| Literature DB >> 35529318 |
Jun Funatsu1, Yusuke Murakami1, Shotaro Shimokawa1, Shunji Nakatake1, Kohta Fujiwara1, Ayako Okita1, Masatoshi Fukushima1, Kensuke Shibata1,2, Noriko Yoshida1,3, Yoshito Koyanagi1, Masato Akiyama1,4, Shoji Notomi1, Shintaro Nakao1, Toshio Hisatomi5, Atsunobu Takeda1, Eleftherios I Paschalis6,7,8, Demetrios G Vavvas6,9, Yasuhiro Ikeda1,10, Koh-Hei Sonoda1.
Abstract
Retinitis pigmentosa (RP) is an intractable inherited disease that primarily affects the rods through gene mutations followed by secondary cone degeneration. This cone-related dysfunction can lead to impairment of daily life activities, and ultimately blindness in patients with RP. Paradoxically, microglial neuroinflammation contributes to both protection against and progression of RP, but it is unclear which population(s) - tissue-resident microglia and/or peripheral monocyte-derived macrophages (mφ) - are implicated in the progression of the disease. Here we show that circulating blood inflammatory monocytes (IMo) are key effector cells that mediate cone cell death in RP. Attenuation of IMo and peripherally engrafted mφ by Ccl2 deficiency or immune modulation via intravenous nano-particle treatment suppressed cone cell death in rd10 mice, an animal model of RP. In contrast, the depletion of resident microglia by a colony-stimulating factor 1 receptor inhibitor exacerbated cone cell death in the same model. In human patients with RP, IMo was increased and correlated with disease progression. These results suggest that peripheral IMo is a potential target to delay cone cell death and prevent blindness in RP.Entities:
Keywords: Nanomedicine; Neuroinflammation; Peripheral monocyte
Year: 2022 PMID: 35529318 PMCID: PMC9075747 DOI: 10.1093/pnasnexus/pgac003
Source DB: PubMed Journal: PNAS Nexus ISSN: 2752-6542